SUMMARY Associations between female sex, HLA B8, positive anti-thyroid microsomal antibody and, to a lesser extent, antinuclear antibody were seen in 34 patients with myasthenia gravis. This supports the concept that the disease is heterogeneous. Anti-DNA antibodies, which were present in 62 % of the patients, did not show such associations.
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Feltkampl postulated the existence of two forms of myasthenia gravis on the basis of associations between certain clinical and immunological features. The first had an early age of disease onset, a female predominance, a high incidence of HLA B8 and thymic hyperplasia, with a low incidence of thymoma and antibodies to skelletal muscle. The second had a later onset, a male predominance, a high incidence of HLA A2 or A3, and a high incidence of thymoma and antibodies to skeletal muscle. 2 This study is an attempt to confirm the heterogeneous nature of the disorder by an investigation of the relationship between HLA phenotype, autoantibody production, patient's sex and age of disease onset. This is a basis for an analysis of the cellular immune characteristics of the disorder to be described subsequently.
Methods

Patients
Thirty-four patients with myasthenia gravis were studied (mean age + s.d. 44 9 years + 15-2; 12 male). All had been diagnosed by consultant neurologists with the support of positive electro-physiological studies or Tensilon test. They represented all patients in the Sheffield area who fulfilled these criteria and who could be traced. Two patients had thymomas without thymectomy, and four others had had thymectomy but not for thymoma. Thymic histology in the remaining 28 patients was considered to be either hyperplasia or involution. Antinuclear antibodies (ANF) were detected in 41 % of the total group and anti-thyroid microsomal antibodies in 32%. If weak positive results (titres less than 1: 80) of these two tests are excluded, the incidence become 6/34 (18%) for ANF, and 7/34 (21 %) for anti-thyroid antibodies. Anti-DNA antibodies (titres all greater than 1: 80) were detected in an unexpected 62 4 of cases.
The incidence of autoantibodies in the few patients with thymoma or who had undergone thymectomy cannot be reliably assessed, but autoantibodies were sometimes detected in patients after thymectomy. Neither of the two patients with thymomas had antithyroid or anti-DNA antibodies and, although both showed positive ANF, this was only weakly so in both cases. Table 2 shows the autoantibody incidence analysed according to the sex of the patient and the presence or absence of HLA B8. Thyroid We observed a surprisingly high incidence of anti-DNA antibodies. To our knowledge, only one other group have previously reported such antibodies in myasthenia gravis. These were detected using a similar haemagglutination method in 400% of cases." The significance of this finding remains at present uncertain. Viral involvement or an immune response to the release of nuclear material after tissue destruction could stimulate the production of such antibodies, but the high incidence and lack of relationship with any clinical or immunological parameter suggests caution should be exercised in its interpretation. Artefactual results produced by the haemagglutination method must be excluded by the confirmation of this finding using other methods. However our technique is not influenced by antibody to denatured (single-stranded) DNA. 5 Considerable supporting evidence has accumulated for an autoimmune pathogenesis in myasthenia gravis since the first suggestion by Simpson.9 The disease overlaps with other putative autoimmune diseases9 and autoantibodies of varying kinds occur more frequently than expected.1 2 6 7 Systemic lupus erythematosus, which is characterised by the production of autoantibodies, shows a selective loss of suppressor cell function10; the clinical associations of autoantibody production in myasthenia gravis shown in this study suggest that a similar loss of suppressor cell function may be associated with the sub-group characterised by HLA B8, female sex and early age of onset.
Acetylcholine receptor antibodies show high specificity to the disease and occur in over 80% of cases." They are pathogenic in rabbits12 and immunoglobulins from human myasthenia have similar effects in mice.13 They show circulating levels in the human disease which correlate with the degree of muscular weakness.14 These features suggest that it is one pathogenic mediator in most cases of the disease. The heterogeneity of myasthenia gravis shown here suggests that several unrelated mechanisms may independently act to lead to its abnormal production.
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